Trials / Unknown
UnknownNCT04517175
Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- Maastricht University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ki-67 is used as a marker for determination of the proliferative activity in solid tumors. The use within hemato-oncological malignancies is limited. This is related to limited technical possibilities of flow cytometry in the past. Meanwhile, flow cytometry in hemato-oncological malignancies has progressed to assessment of 8 colors and makes it possible to add Ki-67 as an additional marker to the 8-color panels. Adding Ki-67 to these panels could lead to improved diagnosis and prediction of therapy response for a number of hemato-oncological malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Flow cytometry | Flow cytometric immunophenotyping and determination of proliferative activity by means of Ki-67. |
Timeline
- Start date
- 2020-09-01
- Primary completion
- 2025-09-01
- Completion
- 2025-09-01
- First posted
- 2020-08-18
- Last updated
- 2020-08-18
Source: ClinicalTrials.gov record NCT04517175. Inclusion in this directory is not an endorsement.